ITERUM THERAP
PharmaITERUM THERAP is a pharmaceutical company focused on Infectious Disease. Key products include ORLYNVAH.
FDA Novel Drug Designations
(2024)See 1 novel approval →
ITERUM THERAP's Key Drugs
ITERUM THERAP's core commercial portfolio centers on ORLYNVAH, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
ITERUM THERAP's Recent FDA Approvals
ITERUM THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ITERUM THERAP's Therapeutic Areas
ITERUM THERAP's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ITERUM THERAP's Top Competitors
ITERUM THERAP's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ITERUM THERAP Pipeline Snapshot
ITERUM THERAP has 7 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 0 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ORLYNVAH leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-10-25
- Latest
- 2025-12-23
- Applications
- 1